Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MLNR | O43193 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619744 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL2778650 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL8249516 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL8251411 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL2779598 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL23911772 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL2778648 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5326481 | 0.99 | MEN1 (0.52) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL8276213 | 0.90 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL10041960 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885683-A2 | A HIGHLY STEREOSELECTIVE SYNTHESIS OF SERTRALINE | Hetero Drugs Limited (IN) | 2008-02-13 | — | — | EP | claimed |
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HETERO DRUGS LIMITED (IN) | 2007-11-08 | — | — | US | claimed |
| WO-2006129324-A2 | A HIGHLY STEREOSELECTIVE SYNTHESIS OF SERTRALINE | HETERO DRUGS LIMITED (IN) | 2006-12-07 | — | — | WO | claimed |
| EP-1885683-A2 | A HIGHLY STEREOSELECTIVE SYNTHESIS OF SERTRALINE | Hetero Drugs Limited (IN) | 2008-02-13 | — | — | EP | disclosed |
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HETERO DRUGS LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| WO-2006129324-A2 | A HIGHLY STEREOSELECTIVE SYNTHESIS OF SERTRALINE | HETERO DRUGS LIMITED (IN) | 2006-12-07 | — | — | WO | disclosed |
| US-6506940-B1 | Converting sertraline stereoisomer into imine form of sertraline; reducing into cis (1S,4S) sertraline and byproduct stereoisomer of sertraline; recovering cis (1S,4S) sertraline from reaction mixture; repeating | SUN PHARMACEUTICALS INDUSTRIES LTD. (IN) | 2003-01-14 | — | — | US | disclosed |
| US-5750794-A | Process for preparing chiral tetralone | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0724552-B1 | PROCESS FOR PREPARING A CHIRAL TETRALONE | PFIZER (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0724552-A1 | PROCESS FOR PREPARING A CHIRAL TETRALONE | PFIZER (US) | 1996-08-07 | — | — | EP | disclosed |
| US-5466880-A | Process for preparing ketone enantiomer | PFIZER INC. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015299-A1 | PROCESS FOR PREPARING A CHIRAL TETRALONE | PFIZER INC. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HTR3A, TPH1, TPH2 | SLC6A2 60/4885SLC6A4 22/4885SLC6A3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.